Копнин Б.П.
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Москва
РЕКОМЕНДУЕМАЯ ЛИТЕРАТУРА
1. Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза. Биохимия, 2000, 65, 5-33.
2. Чумаков П.М. Функция гена р53: выбор между жизнью и смертью. Биохимия, 2000, 65, 34-47.
3. The Genetic Basis of Human Cancer. Eds Vogelstein B., Kinzler, K.W. McGraw Hill, New York, 1998.
4. Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors. Carcinogenesis, 2000, 21, 443-452.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
6. Levine A. J. The tumour suppressor genes. Annu. Rev. Biochem., 1993, 62, 623-651.
7. Weinberg R.A. The molecular basis of oncogenes and tumor suppressor genes. Ann. N.Y. Acad. Sci., 1995, 758, 331-338.
8. Hooper M.L. Tumour suppressor gene mutations in humans and mice: parallels and contrasts. EMBO J., 1998, 17, 6783-6789.
9. Ghebranious N., Donehower L.A. Mouse models in tumor suppression. Oncogene, 1998, 17, 3385-3400.
10. Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA, 1971, 68, 820-823.
11. Grana X., Garriga J., Mayol X. Role of the retinoblastoma protein family, pRb, p107 and p130 in the negative control of cell growth. Oncogene, 1998, 17, 3365-3383.
12. Lipinski M.M., Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene, 1999, 18, 7873-7882.
13. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev., 2000, 14, 2393-2409.
14. Paggi M.G., Giordano A. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res., 2001, 61, 4651-4654.
15. Vogelstein B., Lane D., Levine A. Surfing the p53 network. Nature, 2000, 408, 307-310.
16. Levine A.J. p53, the celular gatekeeper for growth and division. Cell, 1997, 88, p.323 - 331.
17. Woods, D. B. & Vousden, K. H. Regulation of p53 function. Exp. Cell Res., 2001, 264, 56-66.
18. Prives, C. and Hall, P.A. The p53 pathway. J. Path., 1999, 187, 112-126.
19. Sionov R.V., Haupt, Y. The cellular response to p53: the decision between life and death. Oncogene, 1999, 18, 6145 - 6157.
20. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat. Rev. Mol. Cell. Biol., 2000, 1, 199-207.
21. Sherr C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev., 2000, 10, 94-99.
22. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochem. Biophys. Acta, 1998, 1378, F115-F177.
23. Sherr C. J. Parsing Ink4a/Arf: "pure" p16-null mice. Cell, 2001, 106, 531-534.
24. Maehama, T. & Dixon, J. E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol., 1999, 9, 125-128.
25. Bonneau, D. & Longy, M. Mutations of the human PTEN gene. Hum. Mutat., 2000, 16, 109-122.
26. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim.Biophys. Acta, 1997, 1332, F127-F147.
27. Polakis P. The oncogenic activation of b-catenin. Curr. Opin. Genet. Dev., 1999, 9, 15-21.
28. Polakis P. Wnt Signaling and cancer. Genes Dev., 2000, 14, 1837-1851.
29. Polakis P. More than one way to skin a catenin. Cell, 2001, 105, 563-566.
30. Taipale J., Beachy P.A. The Hedgehog and Wnt signaling pathways in cancer. Nature, 2001, 411, 3503-354.
31. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103, 311-320.
32. Massague J., Blain S.W., Lo R.S. TGFb signaling in growth control, cancer, and heritable disorders. Cell, 2000, 103, 295-309.
33. Massague J. How cells read TGF-? signals. Nature Rev. Mol. Cell Biol., 2000, 1, 169-178.
34. Blagosklonny M.V. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors. Oncogene, 2001, 20, 395-398.
35. Gutmann D.H., Hirbe A.C., Haipek C.A. Functiomal analysis of neurofibromatosis 2 (NF2) missense mutations. Hum. Mol.Genet., 2001, 10, 1519-1529.
36. Kinzler, K. W. & Vogelstein, B. Gatekeepers and caretakers. Nature 386, 1997, 761-763.
37. Zhou B.-B.S., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature, 2000, 408, 433-439.
38. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature, 1998, 396, 643-649.
39. Ponder B.A.J. Cancer genetics. Nature, 2001, 411, 336-341.
40. Shiloh, Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet., 1997, 31, 635-662.
41. Kastan M.B., Lim D.S. The many substrates and functions of ATM. Nature Rev. Mol. Cell. Biol., 2000, 1, 179-186.
42. Walworth N.C. Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr. Opin. Cell Biol., 2000, 12, 697-704.
43. Welsh P.A., King M.-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol.Genet., 2001, 10, 705-713.
44. Zheng L., Li S., Boyer T.G., Lee W.-H. Lessons learned from BRCA1 and BRCA2. Oncogene, 2000, 19, 6159-6175.
45. Wang Q., Zhang H., Fishel R., Greene M.I. BRCA1 and cell signaling. Oncogene, 2000, 19, 6152-6158.
46. Kolodner R.D., Marsischky G.T. Eukaryotic DNA mismatch repair. Curr. Opin.Genet. Dev., 1999, 9:89-96.
47. de Laat W.L., Jaspers N.G.J., Hoeijmakers J.H.J. Molecular mechanism of nucleotide excision repair. Gen. Dev., 1999, 13, 768-785.
48. Lehman A.R. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Gen. Dev., 2001, 15, 15-23.
